These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8650087)

  • 1. Hepatotoxic effects of tuberculosis therapy. A practical approach to a tricky management problem.
    Ali J
    Postgrad Med; 1996 May; 99(5):217-20, 230-1, 235-6. PubMed ID: 8650087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.
    Kunimoto D; Warman A; Beckon A; Doering D; Melenka L
    Clin Infect Dis; 2003 Jun; 36(12):e158-61. PubMed ID: 12802781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antituberculosis drugs and hepatotoxicity.
    Yew WW; Leung CC
    Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.
    Tostmann A; Boeree MJ; Aarnoutse RE; de Lange WC; van der Ven AJ; Dekhuijzen R
    J Gastroenterol Hepatol; 2008 Feb; 23(2):192-202. PubMed ID: 17995946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antituberculosis drugs and hepatotoxicity.
    Sharma SK
    Infect Genet Evol; 2004 Jun; 4(2):167-70. PubMed ID: 15157635
    [No Abstract]   [Full Text] [Related]  

  • 6. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
    Jasmer RM; Daley CL
    Am J Respir Crit Care Med; 2003 Mar; 167(6):809-10. PubMed ID: 12623855
    [No Abstract]   [Full Text] [Related]  

  • 7. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
    McElroy PD; Ijaz K; Lambert LA; Jereb JA; Iademarco MF; Castro KG; Navin TR
    Clin Infect Dis; 2005 Oct; 41(8):1125-33. PubMed ID: 16163632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
    JAMA; 2001 Sep; 286(12):1445-6. PubMed ID: 11596606
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatic enzyme abnormalities in children on triple therapy for tuberculosis.
    Corrigan D; Paton J
    Pediatr Pulmonol; 1999 Jan; 27(1):37-42. PubMed ID: 10023790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate.
    Chang KC; Leung CC
    Clin Infect Dis; 2010 Aug; 51(3):366-7; author reply 367-8. PubMed ID: 20597681
    [No Abstract]   [Full Text] [Related]  

  • 11. [Fulminant hepatitis during the therapy for tuberculous meningitis].
    Garavelli PL
    Recenti Prog Med; 1996 Dec; 87(12):597. PubMed ID: 9102699
    [No Abstract]   [Full Text] [Related]  

  • 12. First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform.
    Cao J; Mi Y; Shi C; Bian Y; Huang C; Ye Z; Liu L; Miao L
    Biochem Biophys Res Commun; 2018 Mar; 497(2):485-491. PubMed ID: 29454961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.
    Stout JE; Engemann JJ; Cheng AC; Fortenberry ER; Hamilton CD
    Am J Respir Crit Care Med; 2003 Mar; 167(6):824-7. PubMed ID: 12446275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifampin and pyrazinamide for treatment of latent tuberculosis infection.
    Cook PP
    Clin Infect Dis; 2006 Mar; 42(6):892; author reply 892-3. PubMed ID: 16477576
    [No Abstract]   [Full Text] [Related]  

  • 16. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
    Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
    Gurumurthy P; Ramachandran G; Hemanth Kumar AK; Rajasekaran S; Padmapriyadarsini C; Swaminathan S; Bhagavathy S; Venkatesan P; Sekar L; Mahilmaran A; Ravichandran N; Paramesh P
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4473-5. PubMed ID: 15504887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
    McIlleron H; Wash P; Burger A; Norman J; Folb PI; Smith P
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1170-7. PubMed ID: 16569826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitubercular drugs (isoniazid, rifampin and pyrazinamide): hepatobiliary reactions.
    Vu D; Macdonald L
    CMAJ; 2001 Oct; 165(7):942-3, 946-7. PubMed ID: 11599338
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.
    Ohkawa K; Hashiguchi M; Ohno K; Kiuchi C; Takahashi S; Kondo S; Echizen H; Ogata H
    Clin Pharmacol Ther; 2002 Aug; 72(2):220-6. PubMed ID: 12189369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.